Natera (NASDAQ:NTRA) Price Target Raised to $215.00

Natera (NASDAQ:NTRA) had its target price boosted by Wells Fargo & Company from $205.00 to $215.00 in a research report sent to investors on Friday,Benzinga reports. The firm currently has an equal weight rating on the medical research company’s stock.

A number of other analysts also recently commented on the stock. JPMorgan Chase & Co. boosted their target price on shares of Natera from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Thursday, January 22nd. Canaccord Genuity Group reiterated a “buy” rating on shares of Natera in a research report on Monday, January 12th. BTIG Research raised their price objective on Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a research note on Friday, December 5th. Finally, Evercore boosted their target price on Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $254.47.

Natera Stock Performance

NTRA opened at $208.04 on Friday. Natera has a one year low of $125.38 and a one year high of $256.36. The stock’s fifty day moving average is $226.52 and its 200-day moving average is $204.17. The company has a market capitalization of $28.78 billion, a PE ratio of -135.97 and a beta of 1.65.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.81. Natera had a negative return on equity of 16.71% and a negative net margin of 9.03%.The business had revenue of $665.50 million during the quarter, compared to analysts’ expectations of $600.68 million. During the same quarter last year, the business posted ($0.41) earnings per share. On average, equities research analysts forecast that Natera will post -1.49 EPS for the current fiscal year.

Insider Activity at Natera

In other Natera news, insider Solomon Moshkevich sold 1,639 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $230.77, for a total value of $378,232.03. Following the completion of the sale, the insider owned 137,847 shares in the company, valued at $31,810,952.19. This represents a 1.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Steven Leonard Chapman sold 4,725 shares of Natera stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $230.77, for a total transaction of $1,090,388.25. Following the sale, the chief executive officer directly owned 123,156 shares of the company’s stock, valued at $28,420,710.12. This trade represents a 3.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 360,719 shares of company stock valued at $84,194,824 over the last ninety days. 5.63% of the stock is owned by company insiders.

Hedge Funds Weigh In On Natera

Hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. grew its stake in Natera by 10.5% in the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after purchasing an additional 1,225,420 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Natera by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company’s stock valued at $2,141,594,000 after buying an additional 282,826 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Natera by 94.7% in the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after buying an additional 2,420,263 shares in the last quarter. State Street Corp increased its holdings in Natera by 2.2% in the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock worth $545,624,000 after buying an additional 72,087 shares during the last quarter. Finally, Franklin Resources Inc. raised its position in Natera by 37.5% during the third quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock valued at $428,987,000 after acquiring an additional 727,366 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Quarterly beat — Natera reported Q4 revenue of $665.5M and GAAP EPS of $0.35, well ahead of street estimates (revenue ~$600.7M, EPS loss consensus). The beat supports near-term growth expectations and underpins the stock’s recent strength. Natera Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Favorable clinical data — New Signatera MRD data presented at ASCO GU highlight potential utility across genitourinary cancers (including bladder preservation), which may expand clinical adoption and long-term revenue for Natera’s oncology franchise. Signatera MRD Data at ASCO GU
• Positive Sentiment: Trial results — Natera reported results from the SINERGY trial, another clinical datapoint that could support commercial adoption of its assays. Natera Announces Results From the SINERGY Trial
• Positive Sentiment: Analyst upgrades/targets — Robert W. Baird raised its price target to $257 (outperform) and Wells Fargo raised its target to $215 (equal weight), signaling some sell-side confidence in upside from current levels. Benzinga – Analyst Price Target Changes
• Neutral Sentiment: Full-year revenue guidance roughly in line with consensus — Management issued FY2026 revenue guidance (roughly $2.6B–$2.7B), which appears consistent with street expectations and reduces upside surprise potential from guidance alone. (See Q4 release for guidance details.) Natera Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Analyst consensus — Aggregated analyst coverage remains constructive (average “Moderate Buy”), which supports medium-term expectations but doesn’t preclude short-term volatility. Analyst Average Rating
• Negative Sentiment: Valuation and fundamentals concerns — Despite the beat, Natera still shows negative net margin and negative return on equity on a GAAP basis; combined with a high market capitalization and a recent run-up toward 52-week highs, investors may be taking profits. MarketBeat Q4 Coverage
• Negative Sentiment: Heavy intraday volume and selling pressure — Trading volume was well above average, consistent with a distribution day where some holders trimmed positions after the company’s strong quarter; that drove the stock lower despite the positives. (See intraday volume and price action for context.)

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.